Navigation Links
NewBridge Pharmaceuticals Signs Agreement for Abstral™ for the Middle East and Africa
Date:9/22/2010

DUBAI, United Arab Emirates, Sept. 22 /PRNewswire/ -- NewBridge Pharmaceuticals announced that it has signed an exclusive licensing and distribution agreement with Orexo AB (STO: ORX) that grants NewBridge rights to seek approval for Abstral™, Orexo's product for treatment of breakthrough cancer pain, in the Middle East and Africa and, where approval is granted, to market and sell the product in these territories.  The agreement covers 64 countries across the Middle East and Africa, and excludes Israel where the product is already partnered.

Under the terms of the agreement, Orexo will supply NewBridge with Abstral™ product. The agreement includes milestone and revenue sharing payments; the detailed financial terms are not being disclosed.  NewBridge will also be responsible for managing the regulatory approval process and commercialisation in each of the relevant countries.

Key Points

  • Abstral is a rapidly-disintegrating tablet for sublingual (under the tongue) administration of fentanyl intended for the management of breakthrough pain in cancer patients who are already receiving opioid analgesics for their underlying persistent cancer pain.
  • Abstral was launched in the principal European markets during the course of 2009 and generated sales of 7.4m pounds Sterling in the first six months of 2010 in Europe.
  • Abstral achieved a 24% market share by tablet volume of short-acting fentanyl products in the top five European markets (Source: IMS data, June 2010)
  • Abstral is awaiting a decision from the United States Food & Drug Administration in respect of its approval in the US.

Joe Henein, President and CEO of NewBridge

"Abstral™ is a valuable addition to enhance our growing oncology portfolio.  Across our core geographic region there are man
'/>"/>

SOURCE NewBridge Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NewBridge Pharmaceuticals Completes $12 Million First Close of Series B Financing, Announces Senior Executive Appointments
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Molecular Profiles Ltd., a subsidiary of ... Maryland -based Xceleron have announced a ... clinical development that will be launched at AAPS in ... This partnership extends Molecular Profiles, new ROADMAP to ... this month. The company also has complementary collaborations in ...
(Date:10/30/2014)... 30, 2014  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced an upcoming presentation ... candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates Bind ... given by Sant P. Chawla , M.D., ... principal investigator of the Company,s ongoing global, pivotal ...
(Date:10/30/2014)... October 30, 2014 , ... LGG contribuye a adquirir tolerancia a la proteína ... la proteína de la leche de la vaca (APLV) ... infancia. Hasta ahora, la APLV se trataba eliminando ... ha demostrado que es posible adquirir tolerancia oral ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today reported ... Total revenue was $2.4 million and $5.5 million for the three ... $2.5 million for the same periods in 2010. Total ... 2011, were $7.6 million and $15.0 million as compared to $6.1 ...
... 2011 CORRECTED -- Bionovo, Inc. (NASDAQ: BNVI ... the three months ended June 30, 2011. ... drug candidate, MF101, or Menerba™, during the past quarter, delivering ... and Chief Executive Officer. "We have completed the tasks which ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 9Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 10Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results 11CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 2CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 3CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 4CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results 5
(Date:10/30/2014)... Horse Sense & Sensitivity ... special needs individuals in the Jacksonville area, will be ... from 10-2:00 p.m. at Bailey's Farm (2202 Bishop Estates ... public and is designed to raise awareness and funds ... HSS Round-Up is free. Ticket purchases will be required ...
(Date:10/30/2014)... New York (PRWEB) October 30, 2014 ... Society (NAMS) came to a close on Saturday, ... meeting since the Society’s inception in 1989. NAMS is ... health and quality of life of all women during ... healthy aging. With over 2,000 physicians and thought leaders ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, 2014 (HealthDay ... may have effects on genital development in baby boys, a ... to moms with greater exposure to a chemical called DiNP ... between the genitals and anus. Anogenital distance is set in ... androgens ("male" hormones) during pregnancy. The researchers said their ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- A new vaccine ... meningococcal disease was approved by the U.S. Food and ... protect people between the ages of 10 and 25 ... serogroup B bacteria. The bacteria can infect ... spinal cord and brain. It is a leading cause ...
(Date:10/29/2014)... A new study has found that certain prostate cancer ... from heart-related causes in men with congestive heart failure ... , the findings will help doctors and patients weigh ... Androgen deprivation therapy (ADT), which reduces levels of male ... cancer cells, is a mainstay of treatment for prostate ...
Breaking Medicine News(10 mins):Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2
... FOREST, Ill., April 4, 2008 Hospira,Inc. (NYSE: ... today announced that it will host a conference call ... 2008, at 8 a.m. Central,Time., The company will ... stock market open and the conference call., A ...
... Nurses will hold,a news conference Tuesday, April 8, at ... importance of raising the Medicaid reimbursement rates to,help attract ... more,individuals to benefit from the service of care in ... health care services each,week -- equal to the combined ...
... for warning the public of the risk of a ... among law enforcement officers, according to a study by ... Health and the University of Medicine and Dentistry of ... Cop 2 Cop crisis intervention hotline found no statistically ...
... (Nasdaq: IDIX ) announced today that Idenix management,will ... the upcoming,Canaccord Adams Hepatitis C Conference on Wednesday, April ... Hotel in New York, NY., The live and ... "Calendar of Events" in the Idenix Investor Center at, ...
... Ohio) More than 600,000 children participate in school-sponsored ... Yet gymnastics continues to be overlooked in terms of ... injury rates of all girls sports. , A study, ... and Policy (CIRP) at The Research Institute at Nationwide ...
... 4, 2008 Dialysis,Corporation of America (Nasdaq: DCAI ... its eleventh facility in that state., President & ... our growth in Pennsylvania, one of our core markets ... superior quality,care for the patients we are responsible for ...
Cached Medicine News:Health News:Does raising the terrorism alert level cause undue stress? 2Health News:Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania 2
... Ankle Orthosis enables the clinician to ... ankle joint to control muscle imbalance ... a pair of bilateral turnbuckles, controlling ... Simply adjust the turnbuckle to gradually ...
... Protection,Protects the heel while maintaining the ankle ... contact with a soft, cushioning AliPlast™ foam ... and liner cradles the heel in a ... change position freely in bed from side-lying ...
... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
SCD Sequential Compression System Intermittent Pneumatic Compression...
Medicine Products: